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Functional matrix metalloproteinase-9
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Andre´ M. van Rij, MBChB, MD, Dunedin, New Zealand
Purpose: Matrix metalloproteinase-9 (MMP-9) is a potent endopeptidase with activity against both collagens and elastin.
Expression of MMP-9 is elevated in vascular disease, and in particular within aneurysm tissues. This study tested the
hypothesis that the functionally more active T allele of the MMP9 C-1562T polymorphism may be overrepresented in
patients with abdominal aortic aneurysm (AAA) compared with control subjects and patients with atherosclerotic
peripheral vascular disease (PVD).
Methods: Seven hundred eighty-nine unrelated persons (AAA, n  414; control subjects, n  203; PVD, n  172) were
genotyped for the common C-1562T functional promoter polymorphism of the MMP9 gene.
Results: Genotypes containing the T allele of this polymorphism were significantly more common in patients with AAA
compared with both control subjects and patients with PVD (adjusted odds ratio, 2.41 and 2.94, respectively). The
greatest shift between groups was observed in male patients, with a difference of 20.6% in CT/TT genotypes. and 12.1%
in T allele frequency between patients with AAA compared with patients with PVD.
Conclusions: This study provides further evidence to support the role of MMP-9 in the pathogenesis of AAA, and indicates
that the MMP9 C-1562T functional polymorphism may represent a genetic component contributing to susceptibility to
this vascular disease. (J Vasc Surg 2003;38:1363-7.)
Clinical Relevance: Enzymes that degrade connective tissue components, particularly collagens and elastin, have been
implicated in the pathogenesis of aneurysmal vascular disease. A strong genetic component is associated with suscepti-
bility to abdominal aortic aneurysm (AAA). This study identifies a genetic marker associated with increased production
of matrix metalloproteinase-9, a potent connective tissue protease, which may increase susceptibility to AAA formation.
Clinical screening for such genetic markers might allow future detection of persons at high risk for AAA.
Previously we reported a familial incidence of approxi-
mately 19% within a predominantly white population with
abdominal aortic aneurysm (AAA),1 an observation consis-
tent with a strong genetic component, as described by
other investigators.2,3 The increased frequency of the 5G
allele of an insertion/deletion polymorphism in the pro-
moter region of the plasminogen activator inhibitor-1
(PAI-1) gene in patients with familial AAA compared with
patients with sporadic AAA and control subjects4 also sup-
ports this contention. The PAI-1 5G allele is associated
with reduced PAI-1 transcription and a relative increase in
tissue plasminogen activator activity, and thus may, in turn,
lead to increased activation of matrix metalloproteinase
(MMP) species.5
The MMPs have been widely implicated in the patho-
genesis of both atherosclerosis 6,7 and AAA.8-10 In partic-
ular, MMP-9 appears to be upregulated in both atheroscle-
rotic disease7,11 and aortic aneurysm disease.12-14
However, patterns of cellular expression12 and significantly
higher MMP-9 expression in AAA 8,15 may contribute to
phenotypic differences. Moreover, recent work in trans-
genic mice has raised the possibility that MMPs may have
atheroprotective but proaneurysm activity.16
A relatively common cytosine to thymidine transition at
position 1562 within the promoter region of the MMP9
gene results in an approximately 1.5-fold increase in pro-
moter activity.6 On the basis of known overexpression of
this gene in AAA,8,15 the relative frequency of this func-
tional polymorphism was investigated in patients with AAA
and patients with (atherosclerotic) peripheral vascular dis-
ease (PVD) and compared with a control population.
METHODS
Subjects. In this study 789 unrelated subjects from
the Otago/Southland region of New Zealand were exam-
ined. This population consisted of three groups comprising
patients with AAA (n  414), patients with PVD (n 
172), and a control group (n  203). All AAAs were
greater than 5 cm in diameter, necessitating surgical repair.
A subset of patients with AAA (74/414, 17.9%) were
identified as having a familial history (one or more first-
degree family members with an AAA). PVD was defined as
significant stenosis in multiple segments, including clinical
symptoms such as claudication, rest pain, or tissue loss.
Diagnosis was further confirmed with ankle-brachial index
less than 0.7, pulse volume recordings, and arteriography.
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Patients with PVD also underwent abdominal ultrasound
examination, to exclude those with concurrent AAA. Pa-
tients with PVD were excluded if maximum anteroposte-
rior aortic diameter was greater than 2.5 cm. Control
subjects were recruited from local community groups, with
inclusion criteria of age greater than 55 years and current
good general health.
All subjects were given a questionnaire to ascertain
demographic vascular risk factors. Information collected
included age and gender, and history of hypertension,
hyperlipidemia, diabetes (type collected but grouped for
analysis), stroke, ischemic heart disease, and PVD. Smoking
habits (current and past) were assessed, and the number of
pack-years was calculated (1 pack-year equaled 20 ciga-
rettes per day for 1 year). Plasma samples were also col-
lected, and lipoprotein A (Lp(a)) levels were analyzed with
sandwich enzyme-linked immunosorbent assay.
Genotyping. Genomic DNA was extracted from
blood samples with a modified salting-out procedure, and
were diluted to 50 ng/L. The C to T transition at position
1562 in the MMP9 gene was examined with a modifica-
tion of the method described by Zhang et al.6 In brief, a
polymerase chain reaction (PCR) amplification was con-
ducted with forward (5-CAACGTAGTGAAAC-
CCCATCTCT) and reverse (5-TCCAGGCCCAATTAT-
CACACTTAT) primers. The resulting 379 base-pair (bp)
PCR product was subjected to restriction enzyme digestion
with Bbu1 (Promega Biosciences, San Luis Obispo, Calif)
and was run on a 3% Seakem LE agarose gel (BMA Prod-
ucts, Rockland, Me). Alleles were represented by 379 bp
(C) or 320 bp (T) product bands (Fig).
Undigested PCR product was sequenced (ABI Prism
377 DNA sequencer) to confirm homology with the
MMP9 promoter (GenBank accession number D10051).
Reference samples of both homozygote genotypes were
run with each restriction enzyme digest.
Statistical analysis. Statistical analysis was performed
with StatView version 5.01 (SAS Institute, Cary, NC).
Genotype and allele frequencies were compared with g2
tests. For continuous variables, analysis of variance with the
Fisher protected least significant difference test was per-
formed. Multiple logistic regression was used to test inter-
active effects of variables.
RESULTS
Several significant differences were noted in demo-
graphic factors between groups, including gender ratio,
smoking history (pack-years), plasma Lp(a) level, and his-
tory of hypertension, hypercholesterolemia, and diabetes
(Table I). Number of pack-years, plasma Lp(a) level, and
history of hypertension and hypercholesterolemia were all
greater in patients with AAA or PVD compared with con-
trol subjects. Although the incidence of diabetes in the
PVD group was significantly greater than in the other
groups, there was no significant difference between patients
with AAA and control subjects. The rate of diabetes in
patients with familial AAA was 1.33%, compared with 7.1%
in those with no known family history (sporadic) of AAA (P
 .058) and 6.7% in controls (P .089). Unadjusted odds
ratios for these risk factors, with control subjects as the
reference population, are shown in Table II. A subanalysis
of the control population, excluding those with a history of
ischemic heart disease, resulted in reductions in all demo-
graphic risk factors (Table I), and consequently had the
effect of increasing the odds ratios for demographic risk
factors in both the AAA and PVD groups.
Gender was a significant confounding variable in sev-
eral risk factor parameters, including age (P  .001), hy-
pertension (P  .003), smoking pack-years (P  .0001),
and plasma Lp(a) level (P  .036). All but pack-years were
greater in female patients.
The genotype distributions for the MMP9 C-1562T
polymorphism were in Hardy-Weinberg equilibrium.
There was a significant difference in genotype frequency
between groups, with more CT heterozygotes or TT ho-
mozygotes observed in patients with AAA compared with
control subjects (P  .025) or patients with PVD (P 
.003; Table III). There was no difference between control
subjects and patients with PVD or between patients with
familial or sporadic AAA.
A significant gender difference in the C-1562T poly-
morphism genotype frequency was observed in the total
cohort (P .005). Whereas this effect remained significant
in patients with PVD (P  .001), it was only suggestive in
patients with AAA (P  .117) and not significant in the
control group. Consequently, the greatest frequency shift
was observed after splitting populations by gender, with a
20.6% shift in CT/TT genotypes and a 12.1% shift in T
allele frequency observed between male patients with AAA
Ethidium bromide–stained agarose gel of MMP9 C-1562T geno-
type products. The 379 base pair (bp) polymerase chain reaction
product was digested with BbuI. Sequences with a C allele at the
1562 polymorphic site were not digested by this restriction
enzyme (undigested 379 bp fragment), whereas those with a T
allele were cleaved into two fragments (320 bp fragment visible on
gel). Lanes: M, DNA marker ladder; CC, C allele homozygotes;
TT, T allele homozygote; CT, heterozygotes.
JOURNAL OF VASCULAR SURGERY
December 20031364 Jones et al
and PVD (Table IV), with the rarer T allele associated with
patients with AAA.
Logistic regression analysis of MMP9 C-1562T geno-
type frequency indicated confounding effects by gender,
smoking history (pack-years), and plasma Lp(a). With mul-
tiple logistic regression modeling to account for these
variables, the T allele containing genotypes had an odds
ratio of 2.41 (Table II) in patients with AAA compared
with control subjects, and 2.94 (95% confidence interval,
1.57-5.45) compared with patients with PVD. This rela-
tionship was not significantly altered when modeled with
the control subset without history of ischemic heart disease
as the reference population (Table II).
DISCUSSION
The MMPs represent a family of endopeptidases with
activity against connective tissue matrix proteins. MMP-9
(gelatinase B or 92 kDa type IV collagenase) is a potent
elastase and collagenase that has been implicated in the
pathogenesis of atherosclerosis and aneurysm forma-
tion.5,13,14,17-20 Of interest, however, levels of MMP-9
may be twice as high in aneurysmal arteries compared with
those with occlusive lesions.14,18 Rupture and expansion
rates of AAAs have been linked to MMP-9 levels in tis-
sue21,22 and plasma.23,24 Such observations appear consis-
tent with the increased medial atrophy observed within
AAAs, because activated MMPs may weaken the media by
Table I. Demographic data
Control group
(N  203)
Control subjects with
history of IHD
excluded (N  167)
AAA group
(N  414)
PVD group
(N  172)
Age ( 1 SD) (y) 70.8  8.0 70.1  8.1* 71.7  7.6 72.2  8.8
Gender (% male) 48.0 46.5 72.2† 57.1
Hypertension (%) 33.3‡ 28.3‡ 55.2§ 64.9
Hypercholesterolemia (%) 18.1 11.1‡ 30.0¶ 40.7
Diabetes (%) 6.7 5.6 6.1 24.1#
IHD (%) 17.7** 0 42.6§ 32.0
PVD (%) 0.0‡ 0 23.4† 100
Smoking (pack-years  1 SD) 11.6  19.1‡ 9.8  16.6‡ 31.2  29.7 37.1  37.8
Plasma Lp(a) (nmol/L  1 SD) 50.7  66.7* 46.6  63.8* 76.5  104.3 72.0  97.1
IHD, Ischemic heart disease; AAA, abdominal aortic aneurysm; PVD, peripheral vascular disease; Lp(a), lipoprotein A.
Removal of subjects with history of IHD from control population reduced rates of all demographic risk factors in this group, but did not significantly alter
relationships observed between control group and AAA and PVD groups.
Data represent mean  1 SD.
Significant differences vs: *AAA or PVD (P .05); †control or PVD (P .0001); ‡AAA or PVD (P .0001); §PVD (P .03); AAA (P .004) or PVD (P
 .0001); ¶PVD (P  .002); #AAA or control (P  .0001); **AAA (P  .0001) or PVD (P  .004).
Table II. Odds ratios for groups with vascular disease
Reference group
AAA PVD
All control subjects
Control subjects with
history of IHD excluded All control subjects
Control subjects with
history of IHD excluded
OR CI OR CI OR CI OR CI
Age (y) 1.01 0.99-1.03 1.02 1.002-1.047* 1.02 0.99-1.03 1.03 1.007-1.062*
Gender (male) 3.67 2.56-5.24† 3.90 2.67-5.70† 1.44 0.96-2.17 1.54 1.004-2.35*
Hypertension 2.47 1.72-3.52† 3.12 2.10-4.64† 3.71 2.40-5.71† 4.69 2.95-7.47†
Hypercholesterolemia 1.94 1.27-2.96‡ 2.41 1.49-3.91‡ 3.10 1.92-5.01† 3.86 2.27-6.58†
Diabetes 0.90 0.45-1.79 0.85 0.49-1.92 4.43 2.29-8.58† 5.34 2.50-11.38†
Ischemic heart disease 3.41 2.24-5.18† N/A 2.20 1.33-3.52§ N/A
Smoking (per 10 pack-years) 1.55 1.39-1.74† 1.71 1.50-1.96† 1.64 1.45-1.84† 1.80 1.57-2.07†
Plasma Lp(a) (	75 nmol/L) 1.64 0.99-2.70 1.82 1.05-3.16* 1.52 0.88-2.62 1.65 0.91-2.97
MMP9 C-1562T (T allele) 1.53 1.05-2.23* 1.61 1.07-2.40* 0.84 0.52-1.34 0.88 0.54-1.43
Adjusted MMP9 C-1562T 2.41 1.44-4.02† 2.43 1.38-4.27‡ 0.84 0.41-1.74 0.86 0.41-1.84
AAA, Abdominal aortic aneurysm; PVD, peripheral vascular disease; OR, odds ratio; CI, 95% confidence interval; Lp(a), lipoprotein; MMP, matrix
metalloproteinase.
In AAA group, strongest odds ratios were associated with male gender, history of ischemic heart disease, hypertension, T allele–containing MMP9 genotypes,
and hypercholesterolemia. In contrast, whereas history of hypertension, hypercholesterolemia, and ischemic heart disease were also significant risk factors for
PVD, MMP9 genotype and male gender were not significantly associated with this disease group. Diabetes, which had the greatest odds ratio of any risk factor
in the PVD group, was not associated with AAA.
Odds ratios for the MMP9 T allele were adjusted for significant confounding effects by gender, smoking history (pack-years), and plasma Lp(a).
*P  .05; †P  .0005, ‡P  .005, §P  .01.
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causing destruction of elastic and collagen fibers and
smooth muscle cells.5
In this study, the functional C-1562T MMP9 pro-
moter polymorphism was examined in patients with AAA
compared with both control subjects and patients with
(atherosclerotic) PVD. No differences in either genotype or
allele frequency were observed between control subjects
and patients with PVD. The control population demon-
strated an incidence of the T allele and T allele–containing
genotypes in close accord with that reported previously in
control groups.6,25 Moreover, both the allele and genotype
frequencies in patients with PVD closely matched those
reported in patients with coronary artery disease,26 with T
allele–containing genotype frequency of 25.0% (PVD) ver-
sus 22.9% (coronary artery disease), and T allele frequency
of 12.5% and 12.3%, respectively. On the basis of these
observations, it was therefore not surprising that exclusion
of control subjects with a history of ischemic heart disease
from the reference population had no effect on the MMP9
T allele odds ratios associated with AAA.
There was a clear bias toward CT heterozygotes and TT
homozygotes in patients with AAA compared with both
the control subjects and patients with PVD in this study.
The greatest shift in CT/TT genotype frequency was
20.6%, between male patients with AAA and PVD, with a
corresponding shift in T allele frequency of 12.1%. The T
allele of the C-1562T MMP9 polymorphism is associated
with approximately 50% greater promoter activity than that
of the C allele6; therefore, the observed shift in genotype
and allele frequencies appears consistent with the elevated
expression of MMP-9 in patients with AAA compared with
patients with occlusive atherosclerotic disease.8,27 More-
over, because expression of MMP-9 in AAA is associated
with macrophages within a predominantly inflammatory
environment, the observation of a genetic factor that leads
to increased inducible expression of the MMP9 gene sup-
ports the potential importance of this polymorphism as a
susceptibility factor in AAA.
In this study we observed C-1562T MMP9 gender
effects, which were significant in the PVD group and sug-
gestive in the AAA group, but not observed in the control
group. Of interest, Wang et al26 reported no gender effect
in a relatively large group (n  788) of patients with
coronary artery stenosis. Nevertheless, patient gender rep-
resented a significant confounding factor at logistic regres-
sion analysis in this study.
Smoking history, as measured by the number of pack-
years, was also a confounding variable on C-1562T MMP9
genotype in all three groups examined. This is an interest-
ing observation, given a previously reported associated
between the T allele of this polymorphism and smoking-
induced emphysema.28
Previously, we reported decreased frequency of the 4G
allele in the PAI-1 4G/5G polymorphism in patients with
familial AAA compared with patients with sporadic AAA
and control subjects.4 We hypothesized that this may result
in increased activation of MMPs in the subgroup with
familial AAA. However, we did not observe any difference
between patients with familial and sporadic AAA with
regard to frequency of the MMP9 C-1562T polymorphism
in the current study.
Associations between functional polymorphisms of var-
ious MMPs and aneurysms have also been investigated.
Yoon et al29 examined the association between AAA and
the frequency of a length polymorphism in the CA repeat at
nucleotide positions131 to90 of the MMP9 promoter
as well as the MMP3 5A/6A polymorphism. A suggestive
association between AAA and the MMP3 5A/6A polymor-
phism was described, but no difference in the MMP9
promoter CA repeat length polymorphism was observed. It
should be noted, however, that the study by Yoon et al29
comprised only 47 patients with AAA and was most likely
underpowered. Moreover, the significant association ob-
served in the current study involves a different MMP9
promoter polymorphism.
This report is the first to show that the C-1562T
MMP9 promoter polymorphism is a strong independent
risk factor for AAA. The T allele–containing genotypes of
this polymorphism were associated with AAA with adjusted
odds ratio of 2.41 compared with control subjects. Only
male gender, history of hypertension, and previous isch-
Table III. Genotype and allele frequencies in AAA,
control, and PVD groups (both sexes)
AAA
(N  414)
Control
(N  203)
PVD
(N  172)
Genotype (%)
CC 62.1 71.5 75.0
CT 35.0 28.0 25.0
TT 2.9 0.5 0.0
Allele (%)
C 79.6 85.5 87.5
T 20.4 14.5 12.5
AAA, abdominal aortic aneurysm; PVD, peripheral vascular disease.
Genotype frequency: (2 test, P  .0026), AAA vs Control (P  .030) or
PVD (P  .003), PVD vs Control (P  .505).
Allele frequency: (2 test, P  .263), AAA vs PVD (P  .123), AAA vs
Control (P  .259), PVD vs Control (P  .674).
Table IV. Male genotype and allele frequencies in AAA,
Control, and PVD groups
AAA
(N  320)
Control
(N  97)
PVD
(N  98)
Genotype (%)
CC 63.9 71.9 84.5
CT 32.7 27.0 15.5
TT 3.4 1.1 0.0
Allele (%)
C 79.2 85.4 92.3
T 19.8 14.6 7.7
AAA, abdominal aortic aneurysm; PVD, peripheral vascular disease.
Genotype frequency: (2 test, P  .0019), AAA vs Control (P  .262) or
PVD (P  .0004), PVD vs Control (P  .084).
Allele frequency: (2 test, P  .048), AAA vs PVD (P  .013), AAA vs
Control (P  .334), PVD vs Control (P  .121).
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emic heart disease carried greater risk odds. The greatest
MMP9 T allele odds ratio, 2.94, was observed when the
AAA group was compared with the clinically well-defined
PVD group, in whom AAA had been excluded at ultra-
sound scanning. This observation both highlights the po-
tential importance of this polymorphism as a susceptibility
factor in AAA and supports the notion that AAA and
atherosclerotic occlusive PVD may be distinct pathophysi-
ologic entities.
In conclusion, the functionally more active T variant of
the C-1562T MMP9 polymorphism was significantly asso-
ciated with AAA compared with control or atherosclerotic
PVD. This observation is consistent with the increased
MMP-9 expression observed in aneurysmal aortic disease,
and may represent an important genetic component con-
tributing to AAA susceptibility.
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